Adding Androgen-Receptor Pathway Inhibition with Enzalutamide to Androgen Deprivation Therapy in Prostate Cancer Patients with High-Risk Biochemical Relapse: New Options, New Challenges

Adding Androgen-Receptor Pathway Inhibition with Enzalutamide to Androgen Deprivation Therapy in Prostate Cancer Patients with High-Risk Biochemical Relapse: New Options, New Challenges

Saved in:

Bibliographic Details
Main Author:	Ursula Vogl
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2024-06-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/HBT.OH.2024.20.143
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Anti‐androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals
by: Qiang Dang, et al.
Published: (2015-08-01)

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
by: Tyler Etheridge, et al.
Published: (2019-01-01)

Intermittent androgen therapy in prostate cancer reveals the pro-apoptotic roles of androgen/androgen receptor: an overview
by: Saleh Altuwaijri, et al.
Published: (2025-03-01)

Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer
by: Simeng Wen, et al.
Published: (2020-07-01)

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)

Metabolic changes in patients with prostate cancer with androgen deprivation therapy
by: Maxim N. Peshkov, et al.
Published: (2020-06-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.
by: Chi-Ho Lee, et al.
Published: (2017-01-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Microbial Endocrinology Redefines Prostate Cancer - The Bugs That Outwit Androgen Deprivation
by: Mohammad Asim
Published: (2025-07-01)

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy
by: Safae Terrisse, et al.
Published: (2022-11-01)

The Effect of Androgen Deprivation Therapy on the Cardiovascular System in Advanced Prostate Cancer
by: Allison B. Reiss, et al.
Published: (2024-10-01)

Androgen receptor inhibitors in treating prostate cancer
by: Ryan N Cole, et al.
Published: (2025-03-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Androgen receptor co-regulation in prostate cancer
by: Dhirodatta Senapati, et al.
Published: (2020-07-01)

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer
by: Yongzheng Han, et al.
Published: (2025-07-01)

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer
by: Ruilin Zhuang, et al.
Published: (2025-04-01)

Significance of androgen receptor and its potential for anti-androgen/androgen receptor-antagonist therapy in ovarian cancers.
by: Teresa H Kim, et al.
Published: (2025-01-01)

Skeletal Scintigraphy in Assesing the Response of Prostate Cancer Metastases to Androgen Deprivation Therapy
by: S. P. Mironov, et al.
Published: (2021-09-01)

Comparison of the duration of androgen deprivation therapy in prostate cancer-RADICALS-HD trial
by: Prabhu E. Rajendran
Published: (2025-01-01)

Androgen receptor profiling predicts prostate cancer outcome
by: Suzan Stelloo, et al.
Published: (2015-09-01)

Crosstalk between the Androgen Receptor and PPAR Gamma Signaling Pathways in the Prostate
by: Emuejevoke Olokpa, et al.
Published: (2017-01-01)

Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
by: Lingfan Xu, et al.
Published: (2019-01-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Immunohistochemical expression of androgen receptors in prostate carcinoma and benign prostatic hyperplasia
by: Trivunić-Dajko Sandra, et al.
Published: (2020-01-01)

Secondary Cancer after Androgen Deprivation Therapy in Prostate Cancer: A Nationwide Study
by: Jae Heon Kim, et al.
Published: (2025-01-01)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
by: Jennifer Dunsmore, et al.
Published: (2024-09-01)

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

Role of androgen receptor splice variants in prostate cancer metastasis
by: Jin Xu, et al.
Published: (2016-10-01)

TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocol
by: Colin I Tang, et al.
Published: (2019-08-01)

The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review
by: Renee E. Vickman, et al.
Published: (2020-07-01)

Molecular and Biochemical Effects of a Kola Nut Extract on Androgen Receptor-Mediated Pathways
by: Rajasree Solipuram, et al.
Published: (2009-01-01)

Patient Demographics and Major Adverse Cardiovascular Events after Androgen Deprivation Therapy for Prostate Cancer
by: Christopher J. D. Wallis, et al.
Published: (2024-01-01)

Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer
by: Hang Phuong Pham, et al.
Published: (2022-03-01)

Thresholds of Body Composition Changes Associated with Survival During Androgen Deprivation Therapy in Prostate Cancer
by: Pin-Chi Chen, et al.
Published: (2024-12-01)

Predictors of Fracture Risk and Bone Mineral Density in Men with Prostate Cancer on Androgen Deprivation Therapy
by: Katherine Neubecker, et al.
Published: (2011-01-01)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
by: Ramesh Narayanan
Published: (2020-07-01)

Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives
by: Jieping Hu, et al.
Published: (2017-04-01)

NASP implication in the androgen receptor associated with castration resistance in prostate cancer
by: Yun Feng, et al.
Published: (2025-07-01)